(Q36423867)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

title

Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Maristella Bianconi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Stefano Cascinu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Alessandro Paccapelo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Luciano Burattini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Massimo Cardinali

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Letizia Fabbietti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Roberto Trignani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Franco Rychlicki

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

publication date

5 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

799-801

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

MGMT promoter methylation in malignant gliomas

19 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Recent advances in the treatment of malignant astrocytoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

Response criteria for phase II studies of supratentorial malignant glioma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506588

21 September 2018

Identifiers

DOI

10.3892/OL.2012.788

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

PubMed publication ID

23205103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205103%20AND%20SRC:MED&resulttype=core&format=json